
Pharmaceuticals help people throughout the world live longer, healthier lives. As advances in medical care help more and more people, the need for new medicines to keep people healthy continues to grow.
ChiralVision is a company committed to support pharmaceutical companies developing and producing medicines by providing chiral process development and immobilized enzymes.
Our products and services help pharma to secure efficient production of current and new medicines in development. Focusing on a broad range of technical needs ChiralVision invests significant resources annually in the research and development of new products applicable to all thinkable areas.
Proprietary production of APIs
ChiralVision is the specialist in route development comprising enzymatic conversions [chiral resolution, enantioselective synthesis and regio/chemoselective conversions]. We have an extended experience in process development and scale-up of enzymatically prepared chiral active pharmaceutical ingredients (API). We can help you to develop new and proprietary routes to generic APIs.
Relying on the strength of our knowledge base and scientific talent, ChiralVision has generated a steady stream of breakthroughs over the years resulting in many new patented API production methods.
Chiral APIs and Generics:
A study based on 135 chiral centers in 69 chiral drug syntheses showed the most important sources of chirality are chiral pool (55%) and classical resolution (28%). Larger scale processes tend to move to chemo and / or biocatalytic methods, for reasons of cost effectiveness.
Larger scale API production processes tend to move from chemo to biocatalytic methods for reasons of cost effectiveness.
The food industry utilizes a variety of enzymes for processing of foods. For example immobilized lipases can act on a variety of substrates including natural oils, synthetic triglycerides and esters of fatty acids.
The use of enzymatic technologies for removing contaminants from water provides a safe and economic alternative to commonly used physical-chemical treatment.
The market for industrial enzymes is to expand significantly with the cosmetics industry being one of the principle drivers.